Sean Moran Biography and Net Worth

Mr. Moran has served as our Chief Financial Officer since April 11, 2014. Mr. Moran joined Corbus Pharmaceuticals, Inc. (formerly JB Therapeutics), our wholly-owned subsidiary, as its Chief Financial Officer in January 2014. Mr. Moran has over twenty-five years of senior financial experience with emerging biotechnology, drug delivery and medical device companies. Mr. Moran has worked at three different companies that completed initial public offerings and maintained a listing on a public exchange.

Before joining our company, Mr. Moran served as Director of Finance and then as Chief Financial Officer for InVivo Therapeutics Corporation from 2010 to 2013 and served as Chief Financial Officer of Celsion Corporation from 2008 to 2010, Transport Pharmaceuticals Inc. from 2006 to 2008, Echo Therapeutics Inc. from 2002 to 2006, SatCon Technology Corporation from 2000 to 2002, and Anika Therapeutics Inc. from 1993 to 2000. Mr. Moran is a CPA by training and earned his M.B.A. and a B.S. in Accounting from Babson College.

What is Sean F. Moran's net worth?: The estimated net worth of Sean F. Moran is at least $663.48 thousand as of October 24th, 2025. Moran owns 73,313 shares of Corbus Pharmaceuticals stock worth more than $663,483 as of July 30th. This net worth evaluation does not reflect any other assets that Moran may own. Learn More about Sean F. Moran's net worth.
How do I contact Sean F. Moran?: The corporate mailing address for Moran and other Corbus Pharmaceuticals executives is 500 River Ridge Drive, Norwood MA, 02062. Corbus Pharmaceuticals can also be reached via phone at (617) 963-0100 and via email at [email protected]. Learn More on Sean F. Moran's contact information.
Has Sean F. Moran been buying or selling shares of Corbus Pharmaceuticals?: Sean F. Moran has not been actively trading shares of Corbus Pharmaceuticals during the past quarter. Most recently, Sean F. Moran sold 12,981 shares of the business's stock in a transaction on Friday, October 24th. The shares were sold at an average price of $17.02, for a transaction totalling $220,936.62. Following the completion of the sale, the chief financial officer now directly owns 73,313 shares of the company's stock, valued at $1,247,787.26. Learn More on Sean F. Moran's trading history.
Who are Corbus Pharmaceuticals' active insiders?: Corbus Pharmaceuticals' insider roster includes Anne Altmeyer (Director), Yuval Cohen (CEO), Ian Hodgson (COO), John Jenkins (Director), Winston Kung (Director), Sean Moran (CFO), and Nishant Saxena (Insider). Learn More on Corbus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Corbus Pharmaceuticals?: During the last twelve months, Corbus Pharmaceuticals insiders bought shares 2 times. They purchased a total of 13,500 shares worth more than $101,205.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 86,641 shares worth more than $1,177,188.36. The most recent insider tranaction occured on June, 10th when Director Winston Kung sold 2,026 shares worth more than $16,025.66. Insiders at Corbus Pharmaceuticals own 3.5% of the company. Learn More about insider trades at Corbus Pharmaceuticals.
Information on this page was last updated on 6/10/2026.

Sean F. Moran Insider Trading History at Corbus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/24/2025	Sell	12,981	$17.02	$220,936.62	73,313
6/18/2024	Sell	1,958	$42.12	$82,470.96	48,605
6/14/2024	Sell	9,355	$49.87	$466,533.85	48,605
8/10/2022	Buy	20,000	$0.26	$5,200.00	199,272
5/16/2022	Buy	12,000	$0.30	$3,600.00	179,272
3/10/2022	Buy	15,000	$0.37	$5,550.00
12/21/2020	Sell	87,500	$1.75	$153,125.00	403,220
12/18/2020	Sell	53,610	$1.40	$75,054.00	403,220
12/16/2020	Sell	36,923	$1.32	$48,738.36	386,533
5/14/2019	Buy	100	$7.12	$712.00	349,610
3/14/2019	Buy	1,500	$6.67	$10,005.00	349,510
5/15/2018	Buy	4,000	$5.77	$23,080.00	348,010
3/14/2018	Buy	3,100	$6.60	$20,460.00	344,010
11/10/2017	Buy	1,500	$7.04	$10,560.00	340,910
8/11/2017	Buy	2,500	$5.91	$14,775.00	339,410
5/11/2017	Buy	3,300	$6.14	$20,262.00	336,910
3/13/2017	Buy	2,000	$9.60	$19,200.00	333,610
12/2/2016	Buy	1,500	$7.20	$10,800.00	331,610
9/8/2016	Buy	30,800	$5.12	$157,696.00	330,110
8/26/2016	Buy	17,900	$3.92	$70,168.00	299,310
8/18/2016	Buy	148,960	$3.32	$494,547.20	216,410
5/19/2016	Buy	27,250	$2.37	$64,582.50	132,450
5/18/2016	Buy	30,000	$2.39	$71,700.00	105,250
12/11/2015	Buy	1,000	$1.56	$1,560.00	75,250
12/10/2015	Buy	1,000	$1.61	$1,610.00	74,250
12/9/2015	Buy	1,000	$1.67	$1,670.00	73,250
12/8/2015	Buy	1,000	$1.68	$1,680.00	72,250
12/7/2015	Buy	1,000	$1.69	$1,690.00	71,250
12/4/2015	Buy	1,000	$1.72	$1,720.00	70,250
12/2/2015	Buy	1,000	$1.79	$1,790.00	69,250
11/24/2015	Buy	1,500	$1.78	$2,670.00	68,250
11/20/2015	Buy	1,500	$1.70	$2,550.00	66,750
11/18/2015	Buy	1,500	$1.71	$2,565.00	65,250
11/17/2015	Buy	1,500	$1.72	$2,580.00	63,750
11/16/2015	Buy	2,000	$1.69	$3,380.00	62,250
9/16/2015	Buy	5,000	$2.12	$10,600.00	60,250
9/15/2015	Buy	5,000	$2.14	$10,700.00	55,250
9/14/2015	Buy	5,000	$1.96	$9,800.00	50,250
9/11/2015	Buy	5,000	$1.85	$9,250.00	45,250
8/21/2015	Buy	1,400	$2.06	$2,884.00	40,250
8/18/2015	Buy	1,000	$1.92	$1,920.00	38,850
6/9/2015	Buy	6,500	$3.00	$19,500.00
12/18/2014	Buy	18,800	$3.36	$63,168.00
12/17/2014	Buy	2,850	$3.46	$9,861.00
12/11/2014	Buy	1,000	$3.98	$3,980.00
12/9/2014	Buy	1,700	$3.98	$6,766.00
12/4/2014	Buy	2,000	$3.20	$6,400.00
12/2/2014	Buy	1,000	$3.03	$3,030.00
11/26/2014	Buy	1,000	$3.05	$3,050.00
11/25/2014	Buy	3,000	$3.05	$9,150.00

Sean F. Moran Buying and Selling Activity at Corbus Pharmaceuticals

Corbus Pharmaceuticals Company Overview

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Today's Range

Now: $9.05

$8.79

$9.36

50 Day Range

MA: $8.67

$7.38

$11.35

2 Week Range

Now: $9.05

$7.12

$20.56

Volume

138,001 shs

Average Volume

281,647 shs

Market Capitalization

$167.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.55